Skip to main content

Table 2 Seroprevalence of SARS-COV-2 in first (general population) and second phases by city

From: Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study

City

Phases

Number, n/N

Crude

(95% CI)

Weighted

(95% CI)a

Adjusted for test

performance I

(95% CI)b

Adjusted for test

performance II

(95% CI)c

Ahvaz

First phase

8/100

8.0 (3.5-15.5)

7.9 (2.2-15.9)

9.4 (0.7-21.6)

8.7 (0.6-20.1)

Second phase

57/393

14.5 (11.2-18.4)

17.7 (5.1-30.3)

20.4 (0.5-40.2)

18.9 (0.6-37.2)

Ardabil

First phase

11/87

12.6 (6.5-21.5)

14.8 (3.9-32.3)

20.0 (3.2-46.8)

18.6 (3.0-43.5)

Second phase

115/384

29.9 (25.4-34.8)

28.8 (22.8-34.8)

34.1 (24.2-44.0)

31.7 (22.7-40.7)

Babol

First phase

19/91

20.9 (13.1-30.7)

16.4 (9.6-24.6)

22.4 (11.9-35.1)

20.8 (11.1-32.6)

Second phase

100/383

26.1 (21.8-30.8)

23.1 (14.3-31.8)

27.0 (16.6-37.4)

25.1 (15.3-34.9)

Gorgan

First phase

41/125

32.8 (24.7-41.8)

30.4 (22.3-39.7)

43.9 (31.4-58.3)

40.9 (29.2-54.2)

Second phase

62/330

18.8 (14.7-23.4)

22.4 (10.7-34.1)

26.1 (6.9-45.4)

24.3 (6.9-41.7)

Hamedan

First phase

8/108

7.4 (3.5-15.2)

7.2 (2.9-12.9)

8.3 (1.6-17.0)

7.7 (1.5-15.8)

Second phase

116/391

29.7 (25.2-34.5)

27.5 (21.7-33.3)

32.4 (22.3-42.6)

30.1 (20.7-39.6)

Kerman

First phase

10/108

9.3 (4.5-16.4)

7.1 (3.2-12.6)

8.2 (2.2-16.6)

7.7 (2.1-15.4)

Second phase

64/355

18.0 (14.2-22.4)

14.5 (9.3-19.7)

16.0 (10.7-21.4)

14.9 (9.8-20.0)

Kermanshah

First phase

14/133

10.6 (5.9-17.1)

13.1 (5.3-21.9)

17.3 (5.3-30.9)

16.1 (4.9-28.8)

Second phase

92/389

23.6 (19.5-28.2)

24.1 (17.4-30.7)

28.3 (15.9-40.7)

26.3 (14.5-38.1)

Mashhad

First phase

21/176

11.9 (7.5-17.6)

11.5 (7.1-16.8)

14.8 (8.2-23.1)

13.8 (7.6-21.5)

Second phase

171/691

24.7 (21.6-28.1)

24.7 (17.7-31.7)

35.2 (23.6-46.8)

32.7 (21.2-44.2)

Qom

First phase

48/108

44.4 (34.8-54.3)

39.9 (26.0-56.4)

58.5 (37.2-83.9)

54.4 (34.6-78.0)

Second phase

114/385

29.6 (25.1-34.4)

27.2 (18.1-36.2)

29.8 (24.0-35.6)

32.0 (25.9-38.2)

Sanandaj

First phase

4/96

4.2 (1.1-10.3)

2.7 (0.6-5.7)

1.7 (0.0-6.0)

1.6 (0.0-5.6)

Second phase

117/388

30.1 (25.6-35.0)

27.9 (22.2-33.6)

33.0 (27.3-38.6)

30.7 (25.3-36.1)

Sari

First phase

22/175

12.6 (8.0-18.4)

11.4 (6.9-16.4)

14.7 (7.8-22.4)

13.7 (7.3-20.8)

Second phase

74/400

18.5 (14.8-22.7)

15.9 (9.0-22.7)

17.8 (11.0-24.5)

16.5 (9.8-23.2)

Shiraz

First phase

10/124

8.1 (3.9-15.0)

6.6 (2.6-11.20

7.3 (1.2-14.5)

6.8 (1.1-13.5)

Second phase

90/485

18.6 (15.2-22.3)

18.1 (13.1-23.2)

25.4 (13.6-37.1)

23.6 (12.5-34.7)

Tabriz

First phase

8/103

7.8 (3.4-14.7)

5.4 (1.7-10.2)

5.6 (0.0-13.0)

5.2 (0.0-12.1)

Second phase

180/485

37.1 (32.8-41.6)

32.8 (24.7-40.8)

39.2 (33.0-45.5)

36.5 (30.8-42.2)

Tehran

First phase

191/1572

12.1 (10.6-13.9)

12.4 (10.6-14.5)

16.3 (13.5-19.5)

15.1 (12.5-18.2)

Second phase

271/1181

22.9 (20.6-25.4)

24.9 (20.0-29.8)

35.5 (27.1-43.9)

33.0 (25.0-41.0)

Urmia

First phase

8/101

7.9 (3.5-15.0)

8.4 (1.9-17.6)

10.0 (0.2-24.3)

9.3 (0.2-22.6)

Second phase

66/389

17.0 (13.4-21.1)

18.4 (12.4-24.3)

20.8 (9.0-32.5)

19.3 (8.2-30.4)

Zahedan

First phase

8/105

7.6 (3.3-14.5)

9.7 (3.3-16.9)

12.1 (2.3-23.3)

11.3 (2.1-21.6)

Second phase

75/382

19.6 (15.8-24.0)

16.2 (9.8-22.6)

18.0 (7.6-28.4)

16.7 (7.3-26.1)

  1. Seroprevalence data are % (95% confidence interval). aWeighted by age and sex for each city population·bWeighted prevalence adjusted for test performance I (sensitivity 66·9% and specificity 98.2%). cWeighted prevalence adjusted for test performance II as reported by manufacturer (sensitivity 71.8% and specificity 98.2%). Sample sizes of the first and second phases were 3530 and 7411, respectively
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us